A panelist discusses how emerging chronic myeloid leukemia treatment advancements, including the addition of asciminib as a frontline tyrosine kinase inhibitor (TKI) option and ongoing research into dual TKI therapy and optimal dosing strategies, are expanding therapeutic choices while pharmacists play a key role in educating patients and providers about evolving treatment algorithms, evaluating new literature, and helping teams manage newer agents with less clinical experience.